Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 10/20 | 0.44 |
| ▸ | F2 | P00734 | 8/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907733 | 0.88 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4EHTTLMNA | |
| SCHEMBL2907786 | 0.86 | ALDH1A1 (0.61) | ALDH1A1KDM4EHTTLMNARAB9A | |
| SCHEMBL2908845 | 0.84 | ALDH1A1 (0.52) | ALDH1A1GAAKDM4EHTTLMNA | |
| SCHEMBL2908994 | 0.84 | ALDH1A1 (0.52) | ALDH1A1GAAKDM4EHTTLMNA | |
| SCHEMBL2908333 | 0.83 | KDM4E (0.51) | ALDH1A1GAAKDM4EHTTLMNA | |
| SCHEMBL2905922 | 0.83 | ALDH1A1 (0.52) | ALDH1A1GAAKDM4EHTTLMNA | |
| SCHEMBL2902226 | 0.82 | SSTR5 (0.49) | ALDH1A1GAAKDM4EHTTLMNA | |
| SCHEMBL2906089 | 0.82 | ALDH1A1 (0.44) | ALDH1A1GAAKDM4EHTTLMNA | |
| SCHEMBL5228505 | 0.80 | F10 (0.48) | F10F2 | |
| SCHEMBL2908986 | 0.79 | ALDH1A1 (0.45) | ALDH1A1GAAKDM4EHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | HTR1A, HTR1D, HTR5A | ALDH1A1 1336/4885GAA 3375/4885KDM4E 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.